Oncology News | pharmaphorum

News

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Highlight Therapeutics trials second-line melanoma combo aft...

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond.

News

Gilead licenses Jounce immunotherapy for $800m

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million.

News

GSK moves further ahead in BCMA with EU okay for Blenrep

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission.

News

FDA starts quick review of Merck’s MET-targeting lung cancer...

Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer from the FDA after the US regulator started a priority review of the drug,

News

Novartis eyes filings for leukaemia drug asciminib after pha...

A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid leukaemia (CML) in a head-to-head trial, setting up reg

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

Highlight Therapeutics trials second-line melanoma combo aft...

Gilead licenses Jounce immunotherapy for $800m

GSK moves further ahead in BCMA with EU okay for Blenrep

FDA starts quick review of Merck’s MET-targeting lung cancer...

Novartis eyes filings for leukaemia drug asciminib after pha...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks